Latest filing published 03 Mar 2026 for AbbVie Inc., €7.2M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Robert A. Michael, listed as senior executive, appears in our data through filings on AbbVie Inc. shares, published by SEC (Form 4). Between 17 February 2022 and 27 February 2026, the trades on record add up to 19 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 3 March 2026: a share grant of €7.2M, in AbbVie Inc. The median gap between a trade and its publication by SEC (Form 4) is 5 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations